(Albany, United States) As per DelveInsight’s assessment, globally, the Uveal Melanoma Pipeline constitutes 25+ key companies continuously working towards developing 25+ Uveal Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Uveal Melanoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Uveal Melanoma NDA approvals (if any), and product development activities comprising the technology, Intraocular(Uveal) melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Uveal Melanoma pipeline treatment landscape of the report, click here @ Uveal Melanoma Pipeline Outlook
Key Takeaways from the Uveal Melanoma Pipeline Report
- DelveInsight’s Uveal Melanoma Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline treatment therapies.
- The leading Uveal Melanoma Companies working in the market include Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, and others
- Promising Uveal Melanoma Pipeline Therapies in the various stages of development include AEB071, FHD 286, Dacarbazine, Ipilimumab, Pembrolizumab, DYP688, IMCgp100, SD-101, Nivolumab, Dacarbazine, BVD-523, and others
- On March 2023, Foghorn Therapeutics Inc announced a study of phase 1 clinical trials for FHD-286. This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).
- On March 2023, Immunocore Ltd announced a study of phase 2 clinical trials for Dacarbazine. To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator’s Choice of dacarbazine, ipilimumab, or pembrolizumab.
Uveal Melanoma Overview
Uveal melanoma is the most common primary intraocular malignancy in adults. Intraocular is a disease in which malignant cells form in the tissues of the eye. Signs of intraocular melanoma include blurred vision or a dark spot on the iris. While development of uveal melanoma is largely considered to be a sporadic event, certain risk factors including light iris color, light skin color, ability to tan and others predispose individuals to Uveal melanoma.
To explore more information on the latest breakthroughs in the Uveal Melanoma Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight
Uveal Melanoma Emerging Drugs Profile
- BVD-523: BioMed Valley Discoveries, Inc
- AU-011: Aura Biosciences, Inc
- PAC-1: Vanquish Oncology
Uveal Melanoma Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Intraocular (Uveal) melanoma. The companies which have their Intraocular (Uveal) melanoma drug candidates in the most advanced stage, i.e. phase II include BioMed Valley Discoveries, Inc,
Request a sample and discover the recent advances in Uveal Melanoma Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight
Uveal Melanoma Drugs and Companies
- AEB071: Novartis Pharmaceuticals
- FHD-286: Foghorn Therapeutics Inc
- Dacarbazine: Immunocore Ltd
- SD-101: TriSalus Life Sciences Inc
- BVD-523: Dana-Farber Cancer Institute
Uveal Melanoma Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Uveal Melanoma Therapeutics Market include-
Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, and others
Dive deep into rich insights for drugs for Uveal Melanoma Pipeline, click here for Uveal Melanoma Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight
Scope of the Uveal Melanoma Pipeline Report
- Coverage- Global
- Uveal Melanoma Companies- Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, and others
- Uveal Melanoma Therapies- AEB071, FHD 286, Dacarbazine, Ipilimumab, Pembrolizumab, DYP688, IMCgp100, SD-101, Nivolumab, Dacarbazine, BVD-523, and others
- Uveal Melanoma Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Uveal Melanoma Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Intraocular (Uveal) melanoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Intraocular (Uveal) melanoma – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Intraocular (Uveal) melanoma Collaboration Deals
- Late Stage Products (Preregistration)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BVD-523: BioMed Valley Discoveries, Inc
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Intraocular (Uveal) melanoma Key Companies
- Intraocular (Uveal) melanoma Key Products
- Intraocular (Uveal) melanoma- Unmet Needs
- Intraocular (Uveal) melanoma- Market Drivers and Barriers
- Intraocular (Uveal) melanoma- Future Perspectives and Conclusion
- Intraocular (Uveal) melanoma Analyst Views
- Intraocular (Uveal) melanoma Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services